VVOS

Company Overview — What Does Vivos Therapeutics, Inc. Do?

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics, Inc. (VVOS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO R. Kirk Huntsman and employs approximately 160 people. With a market capitalization of $14M, VVOS is one of the notable companies in the Healthcare sector.

Vivos Therapeutics, Inc. (VVOS) Stock Rating — Avoid (April 2026)

As of April 2026, Vivos Therapeutics, Inc. receives a Avoid rating with a composite score of 19.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.VVOS ranks #4,234 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Vivos Therapeutics, Inc. ranks #760 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VVOS Stock Price and 52-Week Range

Vivos Therapeutics, Inc. (VVOS) currently trades at $1.15. The stock lost $0.01 (0.9%) in the most recent trading session. The 52-week high for VVOS is $7.95, which means the stock is currently trading -85.5% from its annual peak. The 52-week low is $1.19, putting the stock -3.4% above its annual trough. Recent trading volume was 157K shares, suggesting relatively thin trading activity.

Is VVOS Overvalued or Undervalued? — Valuation Analysis

Vivos Therapeutics, Inc. (VVOS) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.79x, versus the sector average of 2.75x. The price-to-sales ratio is 0.84x, compared to 1.66x for the average Healthcare stock.

At current multiples, Vivos Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Vivos Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Vivos Therapeutics, Inc. (VVOS) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -667.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -65.9% versus the sector average of -33.1%.

On a margin basis, Vivos Therapeutics, Inc. reports gross margins of 55.9%, compared to 71.5% for the sector. The operating margin is -98.9% (sector: -66.1%). Net profit margin stands at -101.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 67.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VVOS Debt, Balance Sheet, and Financial Health

Vivos Therapeutics, Inc. has a debt-to-equity ratio of 913.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.78x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $12M. Cash and equivalents stand at $3M.

VVOS has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Vivos Therapeutics, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Vivos Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Vivos Therapeutics, Inc. reported revenue of $17M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-17M. Gross margin was 55.9%. Operating income came in at $-16M.

In Q3 2025, Vivos Therapeutics, Inc. reported revenue of $7M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-5M. Gross margin was 58.0%. Revenue grew 75.7% year-over-year compared to Q3 2024. Operating income came in at $-5M.

In Q2 2025, Vivos Therapeutics, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.55. Net income for the quarter was $-5M. Gross margin was 55.2%. Revenue grew -5.8% year-over-year compared to Q2 2024. Operating income came in at $-5M.

In Q1 2025, Vivos Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.45. Net income for the quarter was $-4M. Gross margin was 50.0%. Revenue grew -11.8% year-over-year compared to Q1 2024. Operating income came in at $-4M.

Over the past 8 quarters, Vivos Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $3M to $17M. Investors analyzing VVOS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VVOS Dividend Yield and Income Analysis

Vivos Therapeutics, Inc. (VVOS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VVOS Momentum and Technical Analysis Profile

Vivos Therapeutics, Inc. (VVOS) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

VVOS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Vivos Therapeutics, Inc. (VVOS) ranks #760 out of 838 stocks based on the Blank Capital composite score. This places VVOS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VVOS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VVOS vs S&P 500 (SPY) comparison to assess how Vivos Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

VVOS Next Earnings Date

No upcoming earnings date has been announced for Vivos Therapeutics, Inc. (VVOS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VVOS? — Investment Thesis Summary

The quantitative profile for Vivos Therapeutics, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 30/100) increases portfolio risk.

In summary, Vivos Therapeutics, Inc. (VVOS) earns a Avoid rating with a composite score of 19.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VVOS stock.

Related Resources for VVOS Investors

Explore more research and tools: VVOS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VVOS head-to-head with peers: VVOS vs AZN, VVOS vs SLGL, VVOS vs VMD.